Bankability depends on the exact cannabinoid and jurisdiction. CBD, CBG and CBN bank cleanly; THCA banks where lawful; synthetic and novel cannabinoids are refused.
Ask ten banks whether they will service a "cannabinoid business" and you will get ten different answers — because there is no such thing as a single cannabinoid risk. Bankability turns on the specific compound and the jurisdiction it is sold into, not on the word "cannabis". GetBanked banks lawful cannabinoid operators, including THCA businesses where their products are genuinely legal, and refuses illegal synthetic and novel cannabinoids as a matter of firm policy.
A bank is not assessing "cannabis". It is assessing a specific molecule, in a specific product, sold into a specific market — and each of those variables changes the legal and commercial risk.
Three factors drive the difference. First, legality turns on the compound, its THC content, and the jurisdiction — a product lawful in Switzerland may be a controlled drug in the Netherlands. Second, card-scheme rules and MCC classification: Visa and Mastercard treat cannabinoid merchants through high-risk merchant category codes, which carry surcharges, tighter chargeback thresholds and heightened scrutiny. Third, reputational and regulatory whiplash — compliance teams fear funding a product that is legal on Monday and prohibited on Tuesday.
This is why blanket answers are worthless. A bank that refuses "cannabinoids" is really refusing the compliance cost of telling lawful CBD apart from an illegal synthetic. Our CBD business banking guide covers the CBD-specific picture in depth; this article is the cannabinoid-by-cannabinoid companion.
The practical upshot: the same operator can be perfectly bankable for one product line and completely unbankable for another. Precision about what you actually sell is the foundation of every application.
Cannabinoid: a compound found in the cannabis or hemp plant, or manufactured synthetically, that interacts with the body's endocannabinoid system. The family includes non-intoxicating compounds like CBD as well as intoxicating ones like Delta-9 THC.
THCA (tetrahydrocannabinolic acid): the non-psychoactive acidic precursor to THC that occurs naturally in raw cannabis and hemp. In its raw state, THCA does not produce a "high".
Decarboxylation: the process by which heating THCA converts it into psychoactive Delta-9 THC. This single conversion — the fact that THCA becomes THC when heated — sits behind almost every banking and legal decision made about THCA products.
That is the crux. THCA looks benign on a raw lab sheet, but a regulator (and a bank's compliance team) reads it as "THC waiting to happen". Because heating is trivial and routine, most authorities refuse to treat raw THCA as harmless, and price the product as if the THC were already present.
Understanding this precursor relationship is the difference between an operator who can explain their product to a bank and one who gets declined for looking evasive.
Total THC: the figure most authorities use to assess a product, calculated as Delta-9 THC + (0.877 × THCA). The 0.877 multiplier reflects the mass lost during decarboxylation — it is the theoretical maximum THC the product could yield once heated.
This formula is why "low-THC on paper" is not the same as "legal". A product can show a tiny Delta-9 figure yet still exceed the consumer limit once its THCA content is folded into total THC. An operator quoting only their Delta-9 number is often quoting the wrong number.
Testing method matters, too. Gas chromatography (GC) heats the sample during analysis, converting THCA to THC — so it effectively counts the THCA. High-performance liquid chromatography (HPLC) measures Delta-9 and THCA separately without converting them. A Certificate of Analysis (COA) that only reports HPLC Delta-9 can make a product look compliant when a total-THC assessment would fail it.
For a bank, this is the single most common place applications quietly fall apart: the operator believes their product is under the limit, but the regulator's total-THC maths says otherwise. Present total THC, and name your testing method — it is the fastest way to build credibility.
GetBanked banks lawful cannabinoid businesses only, assessed case by case. Broadly, the non-controlled, hemp-derived cannabinoids are the cleanest to bank, and the synthetic or novel end of the spectrum is refused outright.
We can bank:
We will not bank:
The table below is our working view. Treat it as a starting frame for a conversation, not a legal ruling — the jurisdiction always modifies it.
| Cannabinoid | Typical status | Bankability with GetBanked |
|---|---|---|
| CBD (cannabidiol) | Non-controlled where within THC limits | Bankable — subject to testing & labelling |
| CBG (cannabigerol) | Non-controlled, hemp-derived | Bankable — subject to testing & labelling |
| CBN (cannabinol) | Non-controlled, hemp-derived | Bankable — subject to testing & labelling |
| THCA (raw acid precursor) | Depends on total-THC rules & jurisdiction | Conditional — where lawful, with clean COA |
| HHC / THCP / Delta-8 | Often caught by NPS / psychoactive frameworks | Refused where prohibited or for human consumption |
| Synthetic / semi-synthetic (incl. CBDN) | Prohibited or novel psychoactive in many markets | Refused — firm policy |
Notice that bankability is never a property of the molecule alone. Even the "bankable" rows are conditional on limits, testing and labelling — which is why documentation, not category, decides most applications.
Yes — but conditionally, and only where the specific products are genuinely lawful. THCA is the most misunderstood cannabinoid in banking precisely because raw lab figures flatter it while the total THC calculation and decarboxylation risk tell the real story.
GetBanked frames THCA as where-lawful, never blanket-legal. A THCA flower or concentrate that is legal in one jurisdiction can be treated with the same suspicion as cannabis in another, with real enforcement risk attached. We assess each THCA operator on the exact products, the total-THC figures, the testing method and — critically — the target markets they ship into.
To bank a THCA business, expect to evidence:
If a THCA product is lawful at origin but ships into a market where total-THC rules or flower restrictions catch it, that is not a bankable line — it is an enforcement exposure. The same operator's compliant lines may still be perfectly bankable. For the wider high-risk context, see our high-risk business bank account guide and high-risk payment processing.
The red line is illegal synthetic, semi-synthetic and novel psychoactive cannabinoids. GetBanked refuses these on both legality and risk-policy grounds, and most compliant banks and acquirers do the same.
Synthetic / semi-synthetic cannabinoid: a cannabinoid that is manufactured or chemically converted rather than simply extracted from the plant in its natural form — for example certain HHC, THCP and Delta-8 products created by converting other cannabinoids.
Novel psychoactive substance (NPS): a psychoactive compound not controlled under the older single-drug conventions, captured instead by newer novel-psychoactive-substance or psychoactive-substances frameworks — often on a fast-moving, tightening basis.
Across Europe, many synthetic and novel cannabinoids intended for human consumption are increasingly caught by NPS frameworks, so their status is restrictive and closing, not liberalising. The EU Drugs Agency (EUDA) tracks the emergence of these compounds precisely because they proliferate faster than single-substance controls can keep up. That is exactly the "legal Monday, prohibited Tuesday" risk banks refuse to fund.
CBDN falls on the refused side of our line. We treat it as a synthetic/novel cannabinoid that GetBanked will not bank — on policy and legality grounds — and we make no claim about a specific statute governing it. The point is not to litigate one molecule; it is that the entire synthetic/novel category carries a risk profile no compliant banking partner will underwrite. An operator building a business on these compounds should expect to be de-risked, not onboarded.
If your product line depends on a converted or lab-created psychoactive cannabinoid sold for human consumption, GetBanked is not the right partner — and, candidly, neither is any bank that intends to keep its licence.
Cannabinoid legality is national, granular and moving. The table below maps finished-hemp-product THC limits and the general posture in several key European markets. Confidence: Medium. These figures shift with regulation and enforcement practice — treat them as orientation, not authority.
| Jurisdiction | Finished-product THC limit / posture | Synthetic & novel cannabinoids | Notes |
|---|---|---|---|
| United Kingdom | CBD not a controlled drug per se; product controlled if it contains a controlled cannabinoid above the exempt threshold | HHC, THCP, Delta-8 largely caught by the Psychoactive Substances Act 2016 for human consumption | THCA flower/concentrate is a grey area — treated with the same suspicion as cannabis; real enforcement risk |
| Germany | ~0.2% THC (finished products) | Restricted under NPS frameworks | Total-THC assessment applies |
| France | ~0.3% THC | Restricted under NPS frameworks | Enforcement has tightened |
| Netherlands | Very strict, ~0.05% | Restricted | Among the most conservative in the EU |
| Switzerland | Up to ~1.0% | Restricted | Non-EU; notably more permissive on THC limit |
| Czech Republic | Up to ~1.0% | Restricted | More permissive limit than most EU states |
| General EU | Most states assess total THC; limits and enforcement vary | Restricted under NPS / psychoactive frameworks | THCA sits in an increasingly grey, tightening area |
Verify locally before you act. These limits and postures change, and the interaction between the finished-product limit, the total-THC calculation and local enforcement is what actually determines legality. Official starting points include the UK Home Office on controlled drugs, the UK Food Standards Agency on CBD as a novel food, and the EUDA for the European drugs picture. None of these replaces qualified local counsel in each market you operate in or sell into.
Two practical warnings. Switzerland's and the Czech Republic's higher limits do not travel — a product compliant at ~1.0% is unlawful the moment it ships into a ~0.2% market. And the general European direction on synthetic and novel cannabinoids is one-way: tightening.
Our position is consistent throughout: we bank lawful cannabinoid businesses only, and bankability is assessed case by case on the specific products, testing, labelling and target markets. We do not bank illegal synthetic or novel cannabinoids such as CBDN.
In practice, an assessment looks at:
The operators who onboard fastest are the ones who arrive with clean COAs, a total-THC calculation per market, and honesty about which lines are lawful where. If a previous application has been declined, our bank rejection fix guide explains how to rebuild a file, and our roundup of the best EMIs for high-risk businesses covers the institutions most likely to serve compliant cannabinoid operators.
The businesses we cannot help are those whose model depends on the synthetic/novel end of the spectrum. We would rather tell you that on day one than onboard a relationship that a regulator or scheme will force us to unwind.
This article is general information, not legal advice. Cannabinoid law varies by country and by product, and it changes quickly. Whether a product is "legal" depends on the exact cannabinoid, its THC content, its form and the jurisdiction it is sold into.
Operators must verify the status of every product in every market with qualified local counsel before relying on it. GetBanked assesses bankability case by case and works only with lawful businesses; nothing here is a determination that any specific product is legal or bankable.
It depends entirely on the jurisdiction and the product's total THC. Because heating THCA converts it to THC through decarboxylation, many authorities treat raw THCA with the same suspicion as cannabis. GetBanked can bank THCA businesses only where their specific products are genuinely lawful in every operating and target market, with clean testing and compliant labelling — it is conditional, never blanket-legal.
Because banks and regulators assess total THC — Delta-9 THC plus 0.877 times the THCA — not the Delta-9 figure alone. A product with a tiny Delta-9 number can still exceed the consumer limit once THCA is counted. The testing method matters too: gas chromatography counts THCA by converting it, while HPLC measures the two separately. "Low-THC on paper" is not the same as "legal".
Generally no. Many of these are synthetic, semi-synthetic or novel psychoactive cannabinoids, and across Europe they are increasingly caught by novel-psychoactive-substance frameworks when sold for human consumption. GetBanked refuses illegal synthetic and novel cannabinoids, including CBDN, as a firm risk and legality policy.
Non-controlled, hemp-derived cannabinoids — CBD, CBG and CBN — are the cleanest, provided products stay within local THC limits, are properly tested and are compliantly labelled. Even then, bankability depends on documentation and target markets, so the compound is a starting point, not a guarantee.
No. Switzerland's more permissive ~1.0% THC limit does not travel. A product compliant at origin becomes unlawful the moment it ships into a stricter market such as Germany (~0.2%) or the Netherlands (~0.05%). Bankability is assessed against every jurisdiction you sell into, not just where you are based.
Related Articles
Tell us exactly which cannabinoids you sell and where — submit a free pre-approval and we'll assess your bankability case by case within 24 hours.
Get Free Pre-Approval